Vimarsana
Biggest News Aggregation in the World

Page 8 - Michael Downes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michael Downes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michael Downes Today - Breaking & Trending Today

Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $36.00 Price Target at HC Wainwright - Vimarsana News

Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $36.00 Price Target at HC Wainwright

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Rating) had its target price raised by HC Wainwright from $33.00 to $36.00 in a research report released on Tuesday morning, The Fly reports. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q2 2023 earnings at ($0.70) EPS, Q3 2023 earnings at ($0.83) EPS, Q3 2023 earnings at ($0.83) EPS, […]

Source: wkrb13.com
Xencor (NASDAQ:XNCR) Price Target Cut to $39.00 - Vimarsana News

Xencor (NASDAQ:XNCR) Price Target Cut to $39.00

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Rating) had its target price hoisted by HC Wainwright from $33.00 to $36.00 in a research note released on Tuesday morning, The Fly reports. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q2 2023 earnings at ($0.70) EPS, Q3 2023 earnings at ($0.83) EPS, Q3 2023 earnings at ($0.83) EPS, […]

Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Increased to $36.00 by Analysts at HC Wainwright - Vimarsana News

Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Increased to $36.00 by Analysts at HC Wainwright

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Rating) had its price objective upped by HC Wainwright from $33.00 to $36.00 in a report published on Tuesday morning, The Fly reports. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q2 2023 earnings at ($0.70) EPS, Q3 2023 earnings at ($0.83) EPS, Q3 2023 earnings at ($0.83) EPS, Q4 […]

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Brokerages - Vimarsana News

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Brokerages

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1-year price […]

Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $33.57 - Vimarsana News

Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $33.57

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1-year price objective among […]

Source: wkrb13.com